Felodipine vs hydralazine: a controlled trial as third line therapy
|
|
- Edmund Willis
- 5 years ago
- Views:
Transcription
1 Br. J. clin. Pharmac. (1986), 21, Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension CO-OPERATIVE STUDY GROUP* *Members of the co-operative study group were: Responsible investigators: D. Maclean (Ninewells Hospital, Dundee); B. D. Vallance (Hairmyres Hospital, East Kilbride); R. G. Wilcox (University Hospital, Nottingham); A. L. Muir (Royal Infirmary, Edinburgh). Statistician: R. A. Elton (Medical Computing and Statistics Unit, University of Edinburgh). Monitor: A. S. Readman (Astra Clinical Research Unit, Edinburgh). Co-investigators: E. T. Mitchell (Dundee); M. M. Vallance (East Kilbride); D. Macleod, L. Tucker, C. G. Wathen (Edinburgh) 1 In a placebo-controlled, double-blind, randomized, parallel group study one hundred and one patients with supine diastolic blood pressure - 1 mm Hg phase V, despite treatment with atenolol 1 mg plus chlorthalidone 25 mg once daily also received either felodipine 5-2 mg twice daily or hydralazine 25-1 mg twice daily for 6 weeks. 2 Felodipine achieved a lower supine blood pressure (mean + s.d. 177/ /8-138/82 ± 19/8 mm Hg) than hydralazine (174/ /8-149/ /11 mm Hg), (P <.5/P <.1). Felodipine also lowered supine diastolic blood pressure to < 9 mm Hg more often than hydralazine (42 vs 22 patients, P <.1). 3 The incidence of unwanted effects was similar in both groups. The felodipine treated patients experienced more ankle swelling and flushing than those in the hydralazine group who experienced more headache and minor gastro-intestinal upset. Keywords felodipine hydralazine hypertension Introduction Hydralazine is one preferred 'third line' drug in hypertension (McAreavey et al., 1984). The risk of drug-induced lupus limits its use (Cameron & Ramsay, 1984; Bing & Russell, 198) and calcium antagonists such as nifedipine are now being increasingly used (Murphy et al., 1983). Felodipine is a new dihydropyridine calcium antagonist which, in animals, selectively dilates arterial resistance vessels (Ljung, 1985). It has pronounced antihypertensive effects (Elmfeldt & Hedner, 1983) and is more potent than nifedipine (Ljung, 1985) with a longer elimination half-life (felodipine, 23.5 h (Elmfeldt & Hedner, 1985); nifedipine, 1 h (Raemsch & Sommer, 1983)) in steady state. It has no negative inotropic activity at therapeutic plasma concentrations (Culling et al., 1984). This study compared the therapeutic usefulness of felodipine with that of hydralazine in hypertensive patients uncontrolled despite a fixed,3-adrenoceptor blocker/diuretic combination. Methods Males and females aged 2-75 years, attending the hypertension clinics of the participating hospitals, were studied if their hypertension (WHO grades I-III) required treatment with three drugs, either because of poor efficacy or intolerance to existing therapy. Exclusion criteria were: child-bearing potential; myocardial infarction less than 3 months or cerebrovascular accident less than 6 months prior to entry; significant angina pectoris; 2nd or 3rd degree heart block; significantly impaired liver Correspondence: Dr D. Maclean, Department of Pharmacology and Clinical Pharmacology, Ninewells Medical School, Dundee, UK 621
2 622 Co-operative Study Group function; known previous poor compliance; severe concurrent disease; known contraindications to hydralazine. Existing,B-adrenoceptor blocker and diuretic treatment was standardised to atenolol 1 mg plus chlorthalidone 25 mg (as Tenoretic, Stuart Pharmaceuticals) once daily. Other antihypertensive drugs (hydralazine 19, methyldopa 12, nifedipine 11, captopril 7, prazosin 7 and others 9 patients) were discontinued and placebo felodipine and placebo hydralazine added 2 or 4 weeks before the study vasodilator was started. Study design All patients were studied 2-4 h after taking the morning tablets. Blood pressure (systolic and diastolic phase V) was measured (using the same arm at each visit) in the supine (after 5 min) and standing (after 1 min) positions using a Hawksley random zero sphygmomanometer. Pulse rate was measured over 3 s in each position immediately after blood pressure measurement. Body weight was also measured at each visit. Placebo, felodipine and hydralazine tablets were dispensed in dosette boxes. Returned tablets were counted at each visit. In addition to a fixed combination of atenolol 1 mg and chlorthalidone 25 mg orally once daily throughout, the patients were given placebo felodipine (identical to the 5 mg active tablet) twice daily, and placebo-hydralazine (identical to the 25 mg active tablet) twice daily, for 2 or 4 weeks. If the supine diastolic pressure after 2 weeks exceeded 11 mm Hg or was associated with unacceptable symptoms, patients were randomized within each centre, doubleblind, to the additional vasodilator. Otherwise the run-in treatment was continued for a further 2 weeks and those then with a supine diastolic blood pressure 2 1 mm Hg (phase V, mean of three consecutive readings) were randomised within each centre to receive either felodipine (one 5 mg tablet twice daily) or hydralazine (one 25 mg tablet twice daily). A double-dummy technique was used and individual treatment codes were not broken, except in emergency, until the study was complete. If after 2 weeks of three drug therapy supine diastolic blood pressure 2 9 mm Hg without significant unwanted effects, the dose of vasodilator was doubled to 1 mg felodipine or 5 mg hydralazine each twice daily (otherwise the doses remained unchanged) for the next 2 weeks. Doses could then be doubled again, according to the same criteria, to a maximum of 2 mg twice daily felodipine or 1 mg twice daily hydralazine for the final 2 weeks (otherwise doses again remained unchanged or could be reduced again if unwanted effects had proved troublesome at the previous dose). The total length of the double-blind period was therefore 6 weeks. There were two opportunities to alter the dose of vasodilator for each patient. Routine biochemical and haematological screening was performed at the beginning and end of the study, together with urinalysis. Acetylator phenotype was determined by the dapsone high pressure liquid chromatography method and classified as fast, intermediate or slow in order to look for any correlation between acetylator status and the required dose of hydralazine (Carr et al., 1978). The biotransformation of felodipine was not assessed. Antinuclear factor titre was measured at the beginning and the end of the study for 6 patients. Adverse experiences were recorded at every visit. Statistical methods All available data from all patients were used in the analysis. The two treatment groups were compared by Wilcoxon rank sum tests or chi-square tests as appropriate. Changes from baseline within treatment groups were tested with Wilcoxon signed-ranks tests. Kendall's rank correlation was used to test the relationship between acetylator status and hydralazine dose. The antihypertensive effects of the two treatments were compared between centres by analysis of variance. Results One hundred and one patients (57 males and 44 females) were randomized to active three drug treatments, 51 to felodipine and 5 to hydralazine. Their mean age was 53.4 (s.d. 9.9) years (range years) and all had a supine diastolic blood pressure 2 1 mm Hg despite 2-4 weeks treatment with atenolol plus chlorthalidone in addition to placebo. Sixty-six patients had a 4 week atenolol/chlorthalidone plus placebo run-in; the remaining 35 had a 2 week run-in period because their supine diastolic blood pressure then exceeded 11 mm Hg or was associated with unacceptable symptoms. At randomization, there were no significant differences between the two groups with respect to age, sex distribution, WHO stage or duration of hypertension, mean systolic or diastolic pressure (supine and erect), pulse rate (supine and erect), weight, acetylator phenotype distribution or any laboratory variable.
3 Table 1 Dose distribution at the end of the study Felodopine (mg twice daily) Withdrawn Hydralazine (mg twice daily) Withdrawn * *includes one death due to hypertensive heart disease and one death due to a gliding accident. Compliance was judged by the investigators to be 'good' for 98.8% of the double-blind assessment period; 81% of the dosette boxes were returned empty, and in the other boxes an average of only 2.8 tablets/patient/visit remained (i.e. less than one full dose). There was an even distribution of patients previously treated with hydralazine (nine in the felodipine and 1 in the hydralazine group) but not for those previously treated with the related dihydropyridine nifedipine (two in the felodipine and nine in the hydralazine group). Clinical assessments Dose distribution Fewer patients required dose increments on felodipine than on hydralazine (P <.1). The dose distribution for active vasodilator at the end of dose titration was that shown in Table 1. Two patients on felodipine required dose reduction, one as a result of ankle swelling, the other because of flushing, headache and fatigue. One patient on hydralazine required dose reduction because of fatigue and another temporarily stopped hydralazine due to headache and nausea. Blood pressure (Figure 1) After 6 weeks diastolic blood pressure (P <.1, supine and erect) was lower on felodipine than on hydralazine. Similarly, systolic blood pressure (P <.5, supine and erect) was then lower on felodipine than on hydralazine. There were no significant differences in these effects between centres. Of the six patients requiring 2 mg twice daily felodipine, only two did not reach the target supine diastolic blood pressure of < 9 mm Hg. Twenty of the patients receiving hydralazine required the maximum dose of 1 mg twice daily and fifteen of these had supine diastolic blood pressure > 9 mm Hg at the end of the study. More patients reached the target supine diastolic blood pressure after 6 weeks using felodipine (42) than hydralazine (22) (P <.1) (Figure 2). Felodipine or hydralazine in hypertension ; *- NS 2 E 18 -E e 16 5 :1 E14 cl g 12 c 1 CA 8 E E o1 2C 1ec l1 14C :35 12C I la Q- wii l1' 8C NSI..I NS *, Randofnization NS P <.6 TI L-j Fin'al "I P < ~I'.6 3;NS l P < Random.Ution Final Figure 1 Supine and erect blood pressures (mean + s.d.). Felodipine () compared with hydralazine (x) at randomization and at the end of the study. No significant differences in pulse rate occurred between the two groups at any stage. Unwanted effects, withdrawals and deaths The most frequently reported unwanted effects associated with vasodilator therapy during this study are shown in Table 2. Ankle swelling and flushing were more frequent in the felodipine group, headache and nausea in the hydralazine group. One felodipine-treated patient was withdrawn after 2 weeks (flushing) and one hydralazinetreated patient after 5 days (rash). Two patients died after approximately 4 weeks on hydralazine: a coroner's post-mortem in one recorded death as caused by 'hypertensive heart disease' which was associated with pulmonary
4 624 Co-operative Study Group 13 r I EE 12 I CA C C.a Un : i : : V - * * :: *... * * : *@ 6 L Figure 2 study. I bmg. - 1mg 2 mg Felodipine (twice daily) 25 mg 5 mg 1 mg Hydralazine (twice daily) Supine diastolic blood pressure of all patients according to treatment and dose at the end of the Table 2 Most frequently reported unwanted effects Number ofpatients Unwanted effect Felodipine Hydralazine (n = 51) (n = 5) Headache 5 14 Ankle swelling 11 3 Flushing 8 2 Fatigue 4 5 Dizziness 4 5 Minor gastro-intestinal upset 1 5 oedema. No unwanted effects had been reported by this patient but his blood pressure had not been well controlled (supine blood pressure of 184/98 mm Hg) by the addition of 5 mg hydralazine twice daily. The other patient died as a result of multiple injuries following a gliding accident believed to be unrelated to his medical condition or its treatment. There were no deaths in the felodipine-treated group. The reporting of ankle swelling on felodipine was not associated with weight gain. Laboratory variables There was a fall in mean serum potassium concentration ( (s.d.) to mmol 1[1 (meq l-1)) from baseline to the 6 week measurement on felodipine (P <.1) but a similar fall in the hydralazine group ( to mmol 17' (meq [1)) was not significant; the difference between these two mean falls in serum potassium concentration was not significant. There were no other significant changes in laboratory variables, including liver enzymes and random blood glucose levels or in antinuclear factor titre. The urinalysis showed no abnormality except in one patient from the hydralazine group who developed glycosuria and diabetes mellitus during the study.
5 Fast acetylators (21 patients) tended to require a higher dose of hydralazine than slow (23 patients) or intermediate (four patients) acetylators but these differences were not significant; two patients in the hydralazine group did not have their acetylator status determined. Discussion This is the first completed, double-blind, comparative study of felodipine with hydralazine as the third drug in a large group of hypertensive patients. The combination of atenolol and chlorthalidone was chosen as baseline therapy because of its widespread use in the United Kingdom. Hydralazine was prescribed from the recommended starting dose of 25 mg twice daily to a maximum dose of only 1 mg twice daily because of the risk of developing the lupus syndrome at higher doses (Cameron & Ramsay, 1984; Bing & Russell, 198). Felodipine was prescribed from a starting dose of 5 mg twice daily because at the time the study was designed this initial dose was considered to be the lowest dose with a useful antihypertensive effect and was known to be well tolerated by most patients (Collste et al., 1985). No formal study to determine the dose of felodipine equivalent in hypotensive potency to the starting dose of hydralazine has been published. Having used three dose levels for hydralazine, this dose of felodipine was increased in the same way to a maximum of 2 mg twice daily. This study design allowed at least 2 weeks for the maximum necessary or tolerated dose of either felodipine or hydralazine to express its antihypertensive potential. This interval is well in excess of five times the known elimination half-life for felodipine, 23.5 h, and the very much shorter half-life for hydralazine. Felodipine reduced the blood pressure more effectively than hydralazine in terms of final blood pressure, the change in blood pressure over the 6 week period and the number of patients achieving target (supine diastolic blood Felodipine or hydralazine in hypertension 625 pressure < 9 mm Hg). Hydralazine at the maximum prescribed dose of 1 mg twice daily did not bring the supine diastolic blood pressure below the target for 53% (25) of the patients whereas at the maximum prescribed dose of 2 mg twice daily felodipine was not fully effective in only 16% (eight) of the patients. The two treatment regimens were associated with a similar overall incidence but a different spectrum of mainly vasodilator-related unwanted effects. More of the hydralazine-treated patients reported headache or nausea and more of the felodipine-treated patients reported ankle swelling or flushing. No concomitant increase in weight was observed in those patients reporting ankle swelling, supporting the theory (Elmfeldt & Hedner, 1983) that this oedema may result from pronounced precapillary vasodilatation rather than fluid retention. The apparent hypokalaemic effects of felodipine or hydralazine in combination with atenolol plus chlorthalidone were more marked but not significantly different in the case of felodipine. Although a similar effect of nifedipine in combination with atenolol and bendrofluazide has been reported (Murphy et al., 1983), differences in pre-study diuretic usage prior to the introduction of the long-acting diuretic chlorthalidone may be responsible for these changes whilst on chlorthalidone too; no useful conclusions can therefore be drawn from these observations. No changes in antinuclear factor titre were observed and no symptoms suggestive of the lupus syndrome developed. We conclude that felodipine, at least in the short-term, is a better third line antihypertensive drug than hydralazine. Longer-term studies of its efficacy and acceptability are warranted. We thank our hospital laboratory staffs for their help, and in particular Dr P. E. G. Mitchell, Dundee. We also thank Dr P. A. Meredith, Department of Materia Medica, University of Glasgow for acetylator phenotype determinations. The Astra Clinical Research Unit, Edinburgh, sponsored this study and gave financial support. References Bing, R. F., Russell, G. I., Thurston, H. & Swales, J. D. (198). Hydralazine in hypertension: Is there a safe dose? Br. med. J., 281, Cameron, H. A. & Ramsay, L. E. (1984). The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br. med. J., 289, Carr, K., Oates, J. A., Nies, A. S. & Woosley, R. L. (1978). Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br. J. clin. Pharmac., 6, Collste, P., Danielsson, M., Elmfeldt, D., Feleke, E., Gelin, A., Hedner, T. & Ryden, L. (1985). Long term experience of felodipine on combination with beta-blockade and diuretics in refractory hypertension. Drugs, 29, (Suppl. 2),
6 626 Co-operative Study Group Culling, W., Ruttley, M. S. M. & Sheridan, D. J. (1984). Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease. Br. Heart J., 52, Elmfeldt, D. & Hedner, T. (1983). Felodipine - a new vasodilator, in addition to beta-receptor blockade in hypertension. Eur. J. clin. Pharmac., 25, Elmfeldt, D. & Hedner, T. (1985). Antihypertensive effects of felodipine compared with placebo. Drugs, 29 (Suppl. 2), Ljung, B. (1985). Vascular selectivity of felodipine. Drugs, 29, (Suppl. 2), McAreavey, D., Ramsay, L. E. & Latham, L., McLaren, A. D., Lorimer, A. R., Reid, J. L., Robertson, J. I. S., Robertson, M. P. & Weir, R. J. (1984). 'Third drug' trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. Br. med. J., 288, Murphy, M. B., Scriven, A. J. I. & Dollery, C. T. (1983). Role of nifedipine in treatment of hypertension. Br. med. J., 287, Raemsch, K. D. & Sommer, J. (1983). Pharmacokinetics and metabolism of nifedipine. Hypertension, 5 (Suppl. II, No 4), II-18-II-24. (Received 3 October 1985, accepted 3 January 1986)
Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationfelodipine extended release or nifedipine retard
Br. J. clin. Pharmac. (1990), 30, 871-878 Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard W. A. LITTLER Felodipine United Kingdom Hospital Study
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationcombination (97 ± 8 beats min-'; 65 ± 4 beats cardiac output may be balanced by the vasodilatation
Br J clin Pharmac 1994; 37: 45-51 An assessment of lacidipine and atenolol in mild to moderate hypertension D. LYONS, G. FOWLER, J. WEBSTER, S. T. HALL' & J. C. PETRIE Clinical Pharmacology Unit, Department
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationLABETALOL IN SEVERE AND RESISTANT HYPERTENSION
Br. J. clin. Pharmac. (1979), 8, 13S-17S LABETALOL IN SEVERE AND RESISTANT HYPERTENSION King's College Hospital Renal Unit, Dulwich Hospital, London SE22 8PT, UK 1 The efficacy of labetalol in the treatment
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationhydrochlorothiazide in the treatment of moderate arterial
Br. J. clin. Pharmac. (1987), 23, 65S-69S Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension D. STERU1, M. CHILDS', S. LANCRENON',
More informationAntihypertensive drugs: I. Thiazide and other diuretics:
Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications
More informationVerapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design
Br J Clin Pharmacol 1998; 45: 491 495 Verapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design Juergen Scholze, 1 Peter Zilles 2 & Daniele Compagnone 2 on
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationA long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension
Br. J. clin. Pharmac. (1986), 21, 55S-62S A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension M. H. FRICK', P. HALTTUNEN2, P. HIMANEN3,
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationThe effects of oral nitrendipine and propranolol, alone and in combination, on hypertensive patients with special reference to
Br. J. clin. Pharmac. (1986), 22, 463-467 The effects of oral nitrendipine and propranolol, alone and in combination, on hypertensive patients with special reference to AV conduction M. B. MALTZ, D. W.
More informationLisinopril and nifedipine: No acute interaction in normotensives
Br. J. clin. Pharmac. (1988), 25, 307-313 Lisinopril and nifedipine: No acute interaction in normotensives K. R. LEES & J. L. REID University Department of Materia Medica, Stobhill General Hospital, Glasgow
More informationTILAZEM. Diltiazem hydrochloride 240 mg
Tilazem Capsules Page 1 of 9 TILAZEM Diltiazem hydrochloride SCHEDULING STATUS: S3 PROPRIETARY NAME (AND DOSAGE FORM): TILAZEM 180 CR (controlled-release capsule) TILAZEM 240 CR (controlled-release capsule)
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:
Core Safety Profile Active substance: Bisoprolol Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg P - RMS: FI/H/PSUR/0002/002 Date of FAR: 13.12.2011
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationOPEN EVALUATION OF LABETALOL IN THE TREATMENT OF ANGINA PECTORIS OCCURRING IN HYPERTENSIVE PATIENTS
Br. J. clin. Pharmac. (1979), 8, 25S-29S OPN VALUATION OF LABTALOL IN TH TRATMNT OF ANGINA PTORIS ORRING IN HYPRTIV PATINTS.M.M. BSTRMAN & M. SPNR ardiological Department, St Mary's Hospital, Norfolk Place,
More informationA double-blind comparison of bisoprolol and atenolol in patients with essential hypertension
QJ Med 995; 88:55-5 A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension N.M. WHEELDON, T.M. MacDONALD, N. PRASAD, D. MACLEAN, L. PEEBLES and D.G. McDEVITT From
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationPractolol and bendrofluazide in treatment of hypertension
British Heart Journal, I974, 36, 867-87I. Practolol and bendrofluazide in treatment of hypertension D. B. Galloway, A. G. Beattie, and J. C. Petrie From Department of Therapeutics and Clinical Pharmacology,
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationP-RMS: IE/H/PSUR/0014/002
Core Safety Profile Active substance: Nitroglycerin Pharmaceutical form(s)/strength: Transdermal patch 25mg, 50mg, 75mg (corresponding to 5, 10 and 15mg per 24 hours respectively P-RMS: IE/H/PSUR/0014/002
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationHypertension is a common disease in our
AJH 2000;13:1161 1167 Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on or Trefor O. Morgan, Adrianne Anderson, and Denise Bertram Arthritis and
More informationDRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI
DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI 3. Vasodilators Drugs which dilate blood vessels ( decrease peripheral vascular resistance) by acting on smooth muscle cells through non-autonomic mechanisms:
More informationOnce Daily Felodipine Monotherapy in Mild to Moderate Hypertension
Med. J. Malaysia Vol. 47 No.4 December 99 Once Daily Felodipine Monotherapy in Mild to Moderate Hypertension S.P.Kon H.W.Tan C.T.Chua M.L.Ong Faculty of Medicine, University Hospital, Kuala Lumpur J.Kamsiah
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More information1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril.
SUMMARY 1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril. 2. While diuretics and beta-blockers remain first-line antihypertensive
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More informationOff-white, round, with faceted edges, scored on one side and bearing the inscription IK10 (10mg) or IK20 (20mg).
1 TRADE NAME OF THE MEDICINAL PRODUCT Ikorel 10mg and 20mg Tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Nicorandil 10mg or 20mg For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationComparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic
Thorax 1984;39:340-344 Comparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic asthma RICHARD F WILLEY, RONALD J FERGUSSON, DAVID J GODDEN, GRAHAM K CROMPTON,
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationLarge therapeutic studies in elderly patients with hypertension
(2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacidipine 2 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg lacidipine. Excipient with known
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationranolazine, 375mg, 500mg and 750mg prolonged-release tablets (Ranexa ) SMC No. (565/09) A. Menarini Pharma UK SRL
2 nd Re-Submission ranolazine, 375mg, 500mg and 750mg prolonged-release tablets (Ranexa ) SMC No. (565/09) A. Menarini Pharma UK SRL 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationHypertension. Penny Mosley MRPharmS
Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationMETOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets
METOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets COMPOSITION Each film-coated tablet of Metotrust XL-25 contains: Metoprolol Succinate USP 23.75 mg equivalent to Metoprolol Tartrate 25
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More informationLESSON ASSIGNMENT Given the trade and/or generic name of an adrenergic blocking agent, classify that agent as either an alpha or beta blocker.
LESSON ASSIGNMENT LESSON 8 Adrenergic Blocking Agents. TEXT ASSIGNMENT Paragraphs 8-1 through 8-5. LESSON OBJECTIVES 8-1. Given a group of statements, select the statement that best describes one of the
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationCardiac Output MCQ. Professor of Cardiovascular Physiology. Cairo University 2007
Cardiac Output MCQ Abdel Moniem Ibrahim Ahmed, MD Professor of Cardiovascular Physiology Cairo University 2007 90- Guided by Ohm's law when : a- Cardiac output = 5.6 L/min. b- Systolic and diastolic BP
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationLONITEN PRODUCT INFORMATION LONITEN DESCRIPTION CLINICAL PHARMACOLOGY AI brand of minoxidil tablets
LONITEN PRODUCT INFORMATION AI.082-1 LONITEN brand of minoxidil tablets DESCRIPTION LONITEN (minoxidil) is an orally active peripheral vasodilator. The pure compound is soluble in water to the extent of
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationProf dr Aleksandar Raskovic DIRECT VASODILATORS
Prof dr Aleksandar Raskovic DIRECT VASODILATORS Direct vasodilators Minoxidil (one of the most powerful peripheral arterial dilators) Opening of KATP channels, efflux of K, lose of Ca and smooth muscle
More informationIN THE TREATMENT OF HYPERTENSION
Br. J. clin. Pharmac. (1981), 12, 887-891 A MPARATIVE STUDY OF ATENOLOL AND METOPROLOL IN THE TREATMENT OF HYPERTENSION S. RASMUSSEN, K. ARNUNG, P.C. ESKILDSEN & P.E. NIELSEN Medical Department C, Diakonissestiftelsen,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationfunction in patients with ischaemic heart disease
Br. J. clin. Pharmac. (1986), 22, 319S-324S Calcium antagonist treatment and its effects on left ventricular function in patients with ischaemic heart disease E. A. RODRIGUES, I. M. AL-KHAWAJA, A. LAHIRI
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationComparison of the effects of penbutolol and propranolol on glomerular filtration rate in hypertensive patients with
Br. J. clin. Pharmac. (1986), 22, 469-474 Comparison of the effects of penbutolol and propranolol on glomerular filtration rate in hypertensive patients with impaired renal function J. VAN DER MEULEN,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThe antihypertensive and diuretic effects of amiloride and. of its combination with hydrochlorothiazide
The antihypertensive and diuretic effects of amiloride and of its combination with hydrochlorothiazide The hypotensive effect as well as changes in serum electrolytes and uric acid of amiloride (AM) and
More informationBlood Pressure Management in Acute Ischemic Stroke
Blood Pressure Management in Acute Ischemic Stroke Kimberly Clark, PharmD, BCCCP Clinical Pharmacy Specialist Critical Care, Greenville Health System Adjunct Assistant Professor, South Carolina College
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationComparison of the efficacy of nicardipine and nifedipine in patients with chronic stable angina
Br. J. clin. Pharmac. (1986), 22, 325S33S Comparison of the efficacy of nicardipine and nifedipine in patients with chronic stable angina C. ARMSTROG, J.GARHAM & R. BLACKWOOD Wexham Park Hospital, Slough
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More information(LONG ACTING FORMULATION) AND BENDROFLUAZIDE
Br. J. clin. Pharmac. (1982), 14, 727-732 COMPARATIVE PHARMACOLOGICAL AND PHARMACOKINETIC OBSERVATIONS ON PROPRANOLOL (LONG ACTING FORMULATION) AND BENDROFLUAZIDE ADMINISTERED SEPARATELY AND CONCURRENTLY
More informationANTI- HYPERTENSIVE AGENTS
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationPharmacological management of hypertension
LINIL GUIDNE Pharmacological management of hypertension ernard Higgins and ryan Williams, on behalf of the Guideline Development Group* (edited by Lynne Turner-Stokes) ernard Higgins FRP, Director, National
More informationN-monodesmethyldiltiazem is the predominant metabolite of
Br. J. clin. Pharmac. (1987), 24, 185-189 N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives S. C. MONTAMAT & D. R. ABERNETHY Section on
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationDrug treatment for primary hypertension
7 Drug treatment for primary hypertension PRACTICAL PRESCRIBING IN HYPERTENSION 7.1 Which drugs should be used first-line? 70 7.2 What is an appropriate interval before assessing the response to therapy?
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationEnalapril in heart failure
Br. J. clin. Pharmac. (1984), 18, 163S-167S Enalapril in heart failure M. G. NICHOLLS, H. IKRAM, E. A. ESPINER, M. W. I. WEBSTER & M. A. FITZPATRICK Endocrinology and Cardiology Departments, The Princess
More informationHypertension: an overview of recommended treatment John Vann Jones PhD, FRCP
Drug review Hypertension Hypertension: an overview of recommended treatment John Vann Jones PhD, FRCP Skyline Imaging Ltd Professor Vann Jones provides an overview of the wide range of antihypertensive
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationSponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title
Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel
More informationPharmacology. Drugs affecting the Cardiovascular system (Antianginal Drugs)
Lecture 7 (year3) Dr Noor Al-Hasani Pharmacology University of Baghdad College of dentistry Drugs affecting the Cardiovascular system (Antianginal Drugs) Atherosclerotic disease of the coronary arteries,
More informationpatients Factors affecting the reporting of symptoms by hypertensive
Br. J. clin. Pharmac. (1984), 18, 189S-194S Factors affecting the reporting of symptoms by hypertensive patients M. J. VADEBURG,S. J. W. EVAS2, B. J. KELL', F. BRADSHAW3, W. J. C. CURRIE & W. D. COOPERI
More informationCalculation of Trough-to-Peak Ratio in the Research Unit Setting
A]H 1996; 9:71S-75S Calculation of Trough-to-Peak Ratio in the Research Unit Setting Advantages and Disadvantages Henry L. Elliott and Peter A. Meredith The trough-to-peak ratio for the response to an
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More information